Recalibrated Risk: How Dobbs Reshaped Early-Stage FemTech Venture Capital

Abstract

This study examines how the 2022 Supreme Court decision in Dobbs v. Jackson Women’s Health Organization reshaped early-stage (Seed and Series A) venture capital investment dynamics in the U.S. FemTech sector. Rather than estimating a causal treatment effect using proprietary deal-level datasets, the study employs a theory-driven policy shock case study design that synthesizes aggregated industry funding analyses, regulatory documentation, and peer-reviewed venture capital scholarship. The observation window spans 2018–2024, capturing both the expansionary venture cycle culminating in 2021 and the contractionary environment that followed.

The findings indicate that Dobbs did not produce categorical capital withdrawal from women’s health innovation. Instead, it coincided with structural recalibration in early-stage investment architecture. Post-2022 funding patterns reveal moderated deal counts, increased capital concentration, narrowing stage composition gaps relative to broader healthcare markets, and heightened reliance on syndicated financing. These shifts are consistent with theoretical expectations that regulatory salience increases perceived risk, raises implicit discount rates, and intensifies prevention-oriented evaluation in politically exposed sectors. Although macroeconomic tightening contributed to overall venture contraction, comparative funding patterns suggest sector-specific recalibration beyond uniform market decline. The study contributes to innovation finance scholarship by demonstrating that regulatory shocks reshape not only capital volume but the institutional framing and structural deployment of early-stage venture investment, particularly within gendered and legitimacy-contested markets.